Vascularized Organoids Market (2026 - 2033)

Vascularized Organoids Market Summary

The global vascularized organoids market size was valued at USD 94.3 million in 2025 and is projected to grow from USD 123.5 million in 2026 to USD 908.3 million by 2033, at a CAGR of 33.0% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.0% in 2025. Market growth is driven by increasing adoption of vascularized organoids in drug discovery, disease modeling, regenerative medicine, and personalized medicine, alongside advancements in stem cell technologies, 3D bioprinting, vascularization techniques, and organoid culture systems.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Market Dynamics

The vascularized organoids market is experiencing strong growth, driven by advances in stem cell technologies, 3D bioprinting, organoid culture systems, and vascularization techniques, as well as growing research activity in tissue engineering and regenerative medicine. Growing development of sophisticated in vitro models, coupled with improvements in microfluidics, biomaterials, and automated organoid platforms, is expected to enhance model reproducibility, functionality, and scalability, thereby creating new opportunities for market growth.

Market Concentration & Characteristics

The vascularized organoids industry is characterized by a high degree of innovation, driven by advances in organotypic vascularization, stem cell differentiation, biomaterials, and 3D tissue engineering. Companies and research institutions are developing approaches that improve vascular functionality, maturation, and integration with organoid tissues. For instance, in May 2025, researchers developed vascular network-inspired 3D-printed scaffolds that reduced hypoxia and necrosis in midbrain organoids and improved their physiological and pharmacological responses.

To learn more about this report, Download Free Sample Report

The vascularized organoids industry is experiencing moderate M&A activity, moderate M&A activity, as life science companies seek to strengthen their organoid and advanced cell-culture technology portfolios. For instance, in January 2025, Merck KGaA completed the acquisition of HUB Organoids, expanding its next-generation biology portfolio and integrating organoid technologies with its existing cell culture products and instrumentation.

“The use of organoids offers tremendous potential to improve the drug discovery process.”

- Jean-Charles Wirth, Head of Science and Lab Solutions, Life Science business of Merck

The vascularized organoids industry is influenced by regulatory and ethical considerations related to stem cell research, human-derived biological materials, preclinical testing, and potential therapeutic applications. Increasing emphasis on reproducibility, characterization, quality control, and standardized organoid models is encouraging developers to establish well-defined protocols. The absence of harmonized standards for vascularized organoid production and characterization, however, remains a consideration for broader commercialization.

The vascularized organoids industry is experiencing rapid growth, driven by the development of organ-specific models and advanced vascularization platforms that enhance tissue maturation and functionality. Developers are broadening applications across disease modeling, drug screening, and regenerative medicine. For instance, in March 2025, researchers established vascularized retinal organoids from human induced pluripotent stem cells by integrating vascular components with retinal organoids, supporting the development of organ-specific models for retinal research and disease studies.

The vascularized organoids industry is experiencing moderate regional expansion, supported by increasing research activity and investments in organoid and regenerative medicine technologies across emerging markets. China is emerging as an important research hub, supported by developments in vascularization, organ-on-chip systems, and tissue engineering. For instance, in May 2025, researchers from Fudan University and collaborating Chinese institutions developed a vascularized organoid-on-a-chip platform capable of supporting centimeter-scale organoid cultivation, highlighting regional advances in scalable vascularized organoid technologies.

Analyst Perspective

The vascularized organoids market is expected to witness significant growth, driven by increasing adoption of advanced 3D cell culture models in drug discovery, disease modeling, regenerative medicine, and developmental biology. Growing demand for physiologically relevant models with improved tissue complexity is accelerating the integration of vascular networks into organoid systems. Advancements in stem cell biology, microfluidics, and organ-on-chip technologies, coupled with rising investments in personalized medicine and pharmaceutical research, are expected to support market expansion. Market participants are focusing on developing scalable vascularized organoid platforms and strategic collaborations to enhance model functionality, reproducibility, and research applications.

Products & Services Insights

The kits, reagents & media segment accounted for the largest revenue share of 48.0% in 2025, driven by the recurring consumption of extracellular matrices and hydrogels, growth factors, endothelial cells, and differentiation kits across every vascularized organoid workflow. Unlike instruments, these consumables are repurchased with each experiment, and the growing availability of standardized, ready-to-use kits is lowering the technical barrier for laboratories adopting vascularized models. For instance, STEMCELL Technologies offers the STEMdiff Blood Vessel Organoid Kit, which enables researchers to generate blood vessel organoids containing endothelial cells and pericytes from human pluripotent stem cells without serum screening or extensive protocol optimization, supporting the use of kit-based workflows in disease modeling and drug discovery.

The instruments & platforms segment is expected to register the fastest CAGR of 36.5% over the forecast period, driven by the increasing adoption of microfluidic chips, perfusion systems, and bioprinters that provide controlled flow, improved nutrient and oxygen delivery, and higher experimental throughput. For instance, in June 2025, Emulate, Inc. commercially launched the AVA Emulation System, a self-contained benchtop instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run, combining high-throughput microfluidic culture, environmental control, and real-time imaging. Such platforms are expected to accelerate the uptake of perfused, vascularized tissue models in pharmaceutical research.

Vascularization Approach Insights

The static in vitro methods segment accounted for the largest revenue share of 42.0% in 2025, owing to the widespread use of endothelial co-culture and self-vascularization protocols that can be performed in standard culture plates without specialized flow equipment. Their lower cost, ease of implementation, compatibility with established organoid protocols, and availability of commercial media and cell sources make them the preferred entry point for academic laboratories and early-stage drug screening programs.

The perfused / microfluidic systems segment is expected to register the fastest CAGR of 37.4% over the forecast period, driven by the ability of organ-on-chip and vessel-on-chip platforms to deliver luminal perfusion, reduce necrotic core formation, and support longer-term culture with more physiologically relevant shear stress. Supportive regulatory momentum is further strengthening demand. For instance, in April 2025, the U.S. FDA announced a plan to phase out animal testing requirements in favor of new approach methodologies, including organoids and organ-on-a-chip systems, and later that month the NIH established the Office of Research Innovation, Validation, and Application (ORIVA) to advance human-based research technologies.

Organoid Type Insights

The liver segment accounted for the largest revenue share of 26.0% in 2025, as drug-induced liver injury remains a leading cause of clinical attrition and post-market withdrawal, making hepatic models central to ADME and safety assessment. Vascularization improves hepatocyte function, metabolic zonation, and long-term viability, enhancing the predictive value of liver organoids in preclinical studies. For instance, Emulate, Inc.’s Liver-Chip S1, the first organ-chip admitted to the FDA’s ISTAND program, demonstrated 87% sensitivity and 100% specificity for drug-induced liver injury, reinforcing confidence in human-relevant liver models.

The cardiac segment is expected to register the fastest CAGR of 35.8% over the forecast period, driven by the high burden of cardiovascular disease, the need for improved screening for cardiotoxicity, and growing research into vascularized heart models for developmental and disease studies. For instance, in June 2025, researchers at Stanford Medicine reported an optimized method for growing heart organoids that reliably generate nearly all major cardiac cell types, including a robust network of blood vessels, thereby addressing a key limitation of earlier cardiac organoid models.

Application Insights

The drug discovery segment accounted for the largest revenue share, at 36.0% in 2025, driven by the pharmaceutical industry’s need for human-relevant models that better predict efficacy and safety prior to clinical trials. Vascularized organoids enable target validation, lead optimization, and compound screening in tissues with improved maturity and nutrient transport, helping reduce late-stage attrition. For instance, in May 2025, Vivodyne raised USD 40 million in Series A funding to scale its robotics- and AI-driven platform for testing drug candidates on lab-grown human tissues, including a new 23,000-square-foot facility in South San Francisco.

To learn more about this report, Download Free Sample Report

The precision / personalized medicine segment is expected to register the fastest CAGR of 36.2% over the forecast period, driven by the growing use of patient-derived vascularized organoids to evaluate individual responses to therapies and guide treatment selection, particularly in oncology. Advances in stem cell reprogramming, improved model reproducibility, and increasing clinical interest in functional precision medicine are expected to support segment growth.

End-use Insights

The pharmaceutical & biotechnology companies segment accounted for the largest revenue share of 51.0% in 2025, driven by substantial R&D spending, rising adoption of new approach methodologies in preclinical programs, and the need to reduce reliance on animal models that often fail to predict human outcomes. These companies are increasingly integrating vascularized organoid and organ-on-chip platforms into efficacy, toxicity, and ADME workflows, either in-house or through partnerships with technology providers.

The CROs segment is expected to register the fastest CAGR of 38.6% over the forecast period, driven by the increasing outsourcing of preclinical testing and the limited in-house expertise of many drug developers in generating regulator-ready data from complex in vitro models. CROs are expanding their microphysiological system and organoid-based service offerings, including contract testing and custom model development, to meet rising demand for human-relevant safety and efficacy data.

Regional Insights

North America dominated the vascularized organoids industry, accounting for the largest revenue share of 43.0% in 2025, supported by advanced stem cell research, strong academic-industry collaboration, and increasing development of physiologically relevant organoid models. According to an article published by NIH in May 2025, researchers developed vascular network-inspired scaffolds that improved the functionality of human midbrain organoids, demonstrating continued innovation in vascularized tissue modeling in the region.

To learn more about this report, Download Free Sample Report

U.S. Vascularized Organoids Market Trends

The vascularized organoids industry in the U.S. is expected to grow over the forecast period, supported by strong translational research and increasing development of vascularized models for disease research and therapeutic evaluation. For instance, in July 2025, researchers at the University of North Texas developed vascularized heart organoids with blood-vessel networks to improve the modeling and testing of cardiovascular treatments.

Europe Vascularized Organoids Market Trends

The vascularized organoids market in Europe was identified as a lucrative region in this industry, supported by expanding research programs focused on vascular biology, organoid development, and regenerative medicine. For instance, in April 2025, the European Commission launched the BVO project under the Marie Skłodowska-Curie Actions program to investigate blood-vessel organoids and their role in human development, supporting regional research capabilities.

The UK vascularized organoids market is supported by established stem cell research, advanced in vitro modeling capabilities, and increasing development of physiologically relevant vascular models. For instance, in April 2026, Queen Mary University of London’s Centre for Predictive in vitro Models reported a vascular organoid platform generated from human induced pluripotent stem cells for modeling vascular inflammation, atherosclerosis, vascular calcification, and angiogenesis, highlighting the UK’s expanding capabilities in vascularized organoid research.

The vascularized organoids market in Germany is anticipated to grow significantly over the forecast period, supported by strong biomedical research capabilities and increasing development of advanced human tissue models for disease research and therapeutic development. For instance, in May 2025, researchers at the Max Delbrück Center in Berlin developed a vascularized organoid model of human stem cell-derived pancreatic islets with integrated blood vessels, demonstrating improved beta-cell maturation and insulin secretion and supporting applications in diabetes research and cell-based therapies.

“Non-vascularized organoids had the most immature cells, a greater proportion matured with vascularization, and even more matured by adding nutrient flow through blood vessels. A human cell model of pancreatic islets that closely replicates in-vivo physiology opens up novel avenues for investigating the underlying mechanisms of diabetes.”

- Maike Sander, Scientific Director of the Max Delbrück Center

Asia Pacific Vascularized Organoids Market Trends

Asia Pacific is expected to grow at the fastest CAGR of 38.03% during the forecast period, supported by expanding stem cell research, increasing investments in tissue engineering, and growing development of advanced organoid and organ-on-chip technologies. For instance, in March 2025, researchers at Gifu Pharmaceutical University in Japan developed vascularized retinal organoids from iPS cells, demonstrating their potential for modeling diabetic retinopathy and supporting the region’s expanding capabilities in vascularized organoid research.

The China vascularized organoids market is emerging as a key center for vascularized organoid research, supported by advances in bioprinting, stem cell engineering, and tissue regeneration. For instance, in November 2025, researchers at Sun Yat-Sen University developed pre-vascularized skin organoid models using coaxial 3D printing, integrating vascular channels with organoid microspheres to support wound-healing applications.

The vascularized organoids market in Japan is expected to grow steadily, supported by advanced stem cell research and increasing development of physiologically relevant human tissue models. For instance, in July 2025, researchers at the Institute of Science Tokyo developed human liver organoids containing authentic sinusoidal-like blood vessels, supporting applications in regenerative medicine, drug discovery, and disease modeling.

Latin America Vascularized Organoids Market Trends

The Latin America vascularized organoids market is expected to grow gradually, supported by expanding stem cell research, tissue engineering capabilities, and academic interest in advanced human disease models. Increasing collaborations between research institutions and biotechnology organizations are expected to strengthen regional capabilities and encourage the adoption of vascularized organoid technologies.

MEA Vascularized Organoids Market Trends

MEA vascularized organoids market is expected to grow steadily, supported by increasing research activity in regenerative medicine, tissue engineering, stem cell research, and organoid-based disease modeling. Growing investments in advanced biomedical research infrastructure and collaborations among academic and research institutions are expected to strengthen regional capabilities and support the gradual adoption of vascularized organoid technologies.

Key Vascularized Organoids Company Insights

Several established life science tool providers and specialized technology developers operate in the vascularized organoids market. Their portfolios span cell culture consumables, extracellular matrices, stem cell and differentiation media, organ-on-chip and microphysiological systems, and contract testing services. Leading players include Thermo Fisher Scientific Inc., Corning Incorporated, STEMCELL Technologies, Emulate, Inc., CN Bio Innovations, MIMETAS, InSphero AG, TissUse GmbH, AIM Biotech, and Vivodyne. They maintain a strong market presence through product launches, advances in perfusion and microfluidic platforms, strategic collaborations with pharmaceutical companies, and funding-backed capacity expansion. Their initiatives focus on improving model reproducibility, vascular functionality, throughput, and regulatory acceptance of human-relevant testing methods.

Key Vascularized Organoids Companies:

The following key companies have been profiled for this study on the vascularized organoids market.

• Thermo Fisher Scientific Inc.

• Corning Incorporated

• STEMCELL Technologies

• Emulate, Inc.

• CN Bio Innovations

• MIMETAS

• InSphero AG

• TissUse GmbH

• AIM Biotech

• Vivodyne

Recent Developments

• In August 2026, Bruker announced a majority investment in MIMETAS to expand human physiology-relevant drug discovery capabilities through organ-on-chip and advanced human tissue model technologies, strengthening commercial infrastructure for complex 3D tissue and organoid-based research.
• In May 2026, Tissue Dynamics partnered with Galmed Pharmaceuticals to develop a human-centered chronic cardiac fibrosis model using vascularized, multichambered cardiac organoids with embedded metabolic sensors, expanding vascularized organoid applications in disease modeling and therapeutic research.

"The ability to model chronic human fibrosis in real time and at scale could allow us to investigate interventions that do more than delay disease progression. If we can identify approaches that improve tissue repair and help resolve fibrosis by correcting the underlying metabolic dysfunction, this has the potential to be a game changer for patients and for drug development in this field. This model is one of a kind. By combining vascularized, multichambered human cardiac organoids with continuous metabolic sensing and AI, we can investigate human fibrotic processes with unprecedented precision. This is especially important for metabolic processes such as lipid remodeling and SCD1 activity, where human relevance, timing, and tissue context are essential to understanding disease and therapeutic response."

- Prof. Yaakov Nahmias, Founder and CSO of Tissue Dynamics

• In December 2025, Thermo Fisher Scientific partnered with AIM Biotech to develop vascularized tumoroid models by combining patient-derived tumor organoids, endothelial cells, and fibroblasts within microfluidic platforms, supporting reproducible vascularized organoid models for cancer research and drug screening.

Global Vascularized Organoids Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global vascularized organoids market on the basis of products & services, vascularization approach, organoid type, application, end-use, and region:

• Products & Services Outlook (Revenue, USD Million, 2021 - 2033)

  • Kits, Reagents & Media

  • Instruments & Platforms

  • Services

• Vascularization Approach Outlook (Revenue, USD Million, 2021 - 2033)

  • Static In Vitro Methods

  • Perfused / Microfluidic Systems

  • In Vivo / Transplantation-Based Methods

  • Bioprinted Constructs

• Organoid Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Liver

  • Brain

  • Cardiac

  • Kidney

  • Lung

  • Other

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Drug Discovery

  • Disease Modeling

  • Toxicity Testing

  • Precision / Personalized Medicine

  • Regenerative Medicine & Transplantation

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutes

  • CROs

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The vascularized organoids market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each vascularized organoids segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations